Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>SVN-001 clinical case strengthened. Solvonis has reported two new secondary analyses of the Phase 2 KARE trial of SVN-001, its ketamine-assisted therapy for severe AUD.</li><li>KARE enrolled 96 patients across four arms, with three weekly IV infusions and six months of follow-up.</li><li>The new analysis demonstrated that SVN-001 patients had 67% fewer heavy drinking days (HDD) than placebo at weeks 17 to 20 (p=0.018) with benefits persisting more than four months after treatment. </li></ul>

SVN-001 clinical case strengthened. Solvonis has reported two new secondary analyses of the Phase 2 KARE trial of SVN-001, its ketamine-assisted therapy for severe AUD.KARE enrolled 96 patients across four arms, with three weekly IV infusions and six months of follow-up.The new analysis demonstrated that SVN-001 patients had 67% fewer heavy drinking days (HDD) than placebo at weeks 17 to 20 (p=0.018) with benefits persisting more than four months after treatment. 

SVNS: New Data Sharpens SVN-001's Path to European Expansion

Solvonis Therapeutics

SVNS: New Data Sharpens SVN-001's Path to European Expansion